Robert W. Baird Increases Amedisys (AMED) Price Target to $120.00
Amedisys (NASDAQ:AMED) had its price objective upped by research analysts at Robert W. Baird from $105.00 to $120.00 in a research note issued on Thursday, Stock Target Advisor reports. The brokerage currently has a “neutral” rating on the health services provider’s stock. Robert W. Baird’s price target would suggest a potential upside of 9.81% from the company’s previous close.
Several other research firms have also issued reports on AMED. Bank of America set a $139.00 price target on shares of Amedisys and gave the stock a “buy” rating in a report on Tuesday, September 18th. Cantor Fitzgerald began coverage on shares of Amedisys in a report on Thursday, September 13th. They set a “neutral” rating and a $117.00 price target for the company. Canaccord Genuity began coverage on shares of Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price objective for the company. SunTrust Banks lifted their price objective on shares of Amedisys to $130.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Royal Bank of Canada lifted their price objective on shares of Amedisys to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $95.38.
Amedisys stock opened at $109.28 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21. Amedisys has a 52-week low of $45.60 and a 52-week high of $127.38. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 51.86, a PEG ratio of 1.89 and a beta of 1.00.
In other news, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in AMED. BlackRock Inc. increased its stake in shares of Amedisys by 7.5% in the 2nd quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock valued at $459,945,000 after acquiring an additional 377,153 shares in the last quarter. Acadian Asset Management LLC grew its position in Amedisys by 148.0% in the 2nd quarter. Acadian Asset Management LLC now owns 191,162 shares of the health services provider’s stock valued at $16,338,000 after purchasing an additional 114,077 shares during the period. Sei Investments Co. grew its position in Amedisys by 762.0% in the 2nd quarter. Sei Investments Co. now owns 123,582 shares of the health services provider’s stock valued at $10,562,000 after purchasing an additional 109,246 shares during the period. Pier Capital LLC acquired a new stake in Amedisys in the 2nd quarter valued at $8,770,000. Finally, DE Burlo Group Inc. acquired a new stake in Amedisys in the 2nd quarter valued at $6,892,000. Institutional investors own 93.31% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.